<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Orban, Tihamer</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Abatacept in Patients with New-Onset Type 1 Diabetes: One-Year Follow-Up</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Type 1 diabetes mellitus (T1DM) is an autoimmune disease that is driven by activated T-lymphocytes. To be fully active, immune T-cells need a costimulatory signal in addition to the main antigen-driven signal. A previous study showed that abatacept, a costimulation modulator that prevents full T-cell activation, slowed reduction in b-cell function over 2 years in individuals with recent-onset T1DM [Orban T et al. Lancet 2011]. This article discusses the 1-year follow-up data from the previous 2-year study [NCT00505375].</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>